Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Single-arm, Phase 2 Trial.

This document provides information about a clinical trial in China for the treatment of limited-stage small cell lung cancer (SCLC). The trial aims to evaluate the effectiveness and safety of a new immunotherapeutic strategy that combines neoadjuvant chemotherapy with the antibodies toripalimab and JS004, along with etoposide and platinum chemotherapy. The trial is being conducted by Shanghai Pulmonary Hospital in Shanghai, China, and is expected to be completed by January 31, 2027. The goal of the trial is to achieve a higher complete pathological response rate for SCLC patients. [Extracted from the article]